| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
BIO3 Stock Overview
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally.
Rewards
Risk Analysis
No risks detected for BIO3 from our risk checks.
Biotest Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €34.70 |
| 52 Week High | €44.50 |
| 52 Week Low | €32.10 |
| Beta | 0.46 |
| 1 Month Change | -2.80% |
| 3 Month Change | -2.25% |
| 1 Year Change | 2.97% |
| 3 Year Change | 55.61% |
| 5 Year Change | 57.01% |
| Change since IPO | 450.59% |
Recent News & Updates
Shareholder Returns
| BIO3 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -2.0% | 0.1% | -0.5% |
| 1Y | 3.0% | -34.0% | -21.1% |
Return vs Industry: BIO3 exceeded the German Biotechs industry which returned -34.4% over the past year.
Return vs Market: BIO3 exceeded the German Market which returned -22% over the past year.
Price Volatility
| BIO3 volatility | |
|---|---|
| BIO3 Average Weekly Movement | 2.7% |
| Biotechs Industry Average Movement | 6.9% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.9% |
Stable Share Price: BIO3 is less volatile than 75% of German stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: BIO3's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1946 | 1,967 | Michael Ramroth | https://www.biotest.com |
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas.
Biotest Fundamentals Summary
| BIO3 fundamental statistics | |
|---|---|
| Market Cap | €1.53b |
| Earnings (TTM) | -€54.20m |
| Revenue (TTM) | €511.50m |
2.7x
P/S Ratio-25.3x
P/E RatioIs BIO3 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BIO3 income statement (TTM) | |
|---|---|
| Revenue | €511.50m |
| Cost of Revenue | €427.60m |
| Gross Profit | €83.90m |
| Other Expenses | €138.10m |
| Earnings | -€54.20m |
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
Aug 11, 2022
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 16.40% |
| Net Profit Margin | -10.60% |
| Debt/Equity Ratio | 142.4% |
How did BIO3 perform over the long term?
See historical performance and comparisonDividends
0.1%
Current Dividend Yield-3%
Payout RatioValuation
Is BIO3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
2/6Valuation Score 2/6
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
PEG Ratio
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BIO3?
Other financial metrics that can be useful for relative valuation.
| What is BIO3's n/a Ratio? | |
|---|---|
| n/a Ratio | 0x |
| n/a | n/a |
| Market Cap | €1.53b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 3.8x |
| Enterprise Value/EBITDA | -96.2x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does BIO3's PS Ratio compare to its peers?
| BIO3 PS Ratio vs Peers |
|---|
| Company | PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 25.3x | ||
FYB Formycon | 23x | 33.8% | €852.0m |
MOR MorphoSys | 4x | 29.7% | €691.2m |
HPHA Heidelberg Pharma | 67.9x | 18.3% | €163.0m |
MDG1 Medigene | 6.1x | -16.1% | €63.6m |
BIO3 Biotest | 2.7x | 7.8% | €1.5b |
Price-To-Sales vs Peers: BIO3 is good value based on its Price-To-Sales Ratio (2.7x) compared to the peer average (25.3x).
Price to Earnings Ratio vs Industry
How does BIO3's PE Ratio compare vs other companies in the European Biotechs Industry?
Price-To-Sales vs Industry: BIO3 is good value based on its Price-To-Sales Ratio (2.7x) compared to the German Biotechs industry average (4.7x)
Price to Sales Ratio vs Fair Ratio
What is BIO3's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 2.7x |
| Fair PS Ratio | 1.6x |
Price-To-Sales vs Fair Ratio: BIO3 is expensive based on its Price-To-Sales Ratio (2.7x) compared to the estimated Fair Price-To-Sales Ratio (1.6x).
Share Price vs Fair Value
What is the Fair Price of BIO3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: BIO3 (€34.7) is trading above our estimate of fair value (€15.49)
Significantly Below Fair Value: BIO3 is trading above our estimate of fair value.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate BIO3's PEG Ratio to determine if it is good value.
Discover undervalued companies
Future Growth
How is Biotest forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
4/6Future Growth Score 4/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
104.1%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BIO3 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.05%).
Earnings vs Market: BIO3 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: BIO3 is expected to become profitable in the next 3 years.
Revenue vs Market: BIO3's revenue (7.8% per year) is forecast to grow faster than the German market (4.8% per year).
High Growth Revenue: BIO3's revenue (7.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BIO3's Return on Equity is forecast to be low in 3 years time (4.1%).
Discover growth companies
Past Performance
How has Biotest performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
-21.3%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: BIO3 is currently unprofitable.
Growing Profit Margin: BIO3 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: BIO3 is unprofitable, and losses have increased over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare BIO3's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIO3 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-8.4%).
Return on Equity
High ROE: BIO3 has a negative Return on Equity (-14.45%), as it is currently unprofitable.
Discover strong past performing companies
Financial Health
How is Biotest's financial position?
Financial Health Score
3/6Financial Health Score 3/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: BIO3's short term assets (€523.9M) exceed its short term liabilities (€114.9M).
Long Term Liabilities: BIO3's short term assets (€523.9M) do not cover its long term liabilities (€619.8M).
Debt to Equity History and Analysis
Debt Level: BIO3's net debt to equity ratio (111.6%) is considered high.
Reducing Debt: BIO3's debt to equity ratio has increased from 103.5% to 142.4% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable BIO3 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: BIO3 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 18.2% per year.
Discover healthy companies
Dividend
What is Biotest current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
0.11%
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: BIO3's dividend (0.12%) isn’t notable compared to the bottom 25% of dividend payers in the German market (1.47%).
High Dividend: BIO3's dividend (0.12%) is low compared to the top 25% of dividend payers in the German market (4.53%).
Stability and Growth of Payments
Stable Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are stable.
Growing Dividend: BIO3 is not paying a notable dividend for the German market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: BIO3 is not paying a notable dividend for the German market.
Cash Payout to Shareholders
Cash Flow Coverage: BIO3 is not paying a notable dividend for the German market.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
8.1yrs
Average management tenure
CEO
Michael Ramroth (59 yo)
18.33yrs
Tenure
€2,724,000
Compensation
Dr. Michael Ramroth serves as Chairman of the Management Board and CEO at Biotest Aktiengesellschaft since May 01, 2019. Dr. Ramroth serves as Chief Financial Officer at Biotest Aktiengesellschaft. He serv...
CEO Compensation Analysis
Compensation vs Market: Michael's total compensation ($USD2.89M) is above average for companies of similar size in the German market ($USD1.50M).
Compensation vs Earnings: Michael's compensation has increased whilst the company is unprofitable.
Leadership Team
Experienced Management: BIO3's management team is seasoned and experienced (8.1 years average tenure).
Board Members
Experienced Board: BIO3's board of directors are considered experienced (3.3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Top Shareholders
Company Information
Biotest Aktiengesellschaft's employee growth, exchange listings and data sources
Key Information
- Name: Biotest Aktiengesellschaft
- Ticker: BIO3
- Exchange: XTRA
- Founded: 1946
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €1.525b
- Shares outstanding: 39.57m
- Website: https://www.biotest.com
Number of Employees
Location
- Biotest Aktiengesellschaft
- Landsteinerstrasse 5
- Dreieich
- Hessen
- 63303
- Germany
Listings
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2022/06/27 00:00 |
| End of Day Share Price | 2022/06/27 00:00 |
| Earnings | 2022/03/31 |
| Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.